Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein.
about
Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein.Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesHIV-1 fusion is blocked through binding of GB Virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected]CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodiesAntibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodiesFunctional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region.In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail.Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity.Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activityImmunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity.Residues in the membrane-spanning domain core modulate conformation and fusogenicity of the HIV-1 envelope glycoprotein.Cell surface expression of the HIV-1 envelope glycoproteins is directed from intracellular CTLA-4-containing regulated secretory granules.Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediatesStabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.Increased functional stability and homogeneity of viral envelope spikes through directed evolution.Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirionsChimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses.A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope.Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop.Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.Stability of a receptor-binding active human immunodeficiency virus type 1 recombinant gp140 trimer conferred by intermonomer disulfide bonding of the V3 loop: differential effects of protein disulfide isomerase on CD4 and coreceptor bindingA vaccine for HIV type 1: the antibody perspective.Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.Antibody polyspecificity and neutralization of HIV-1: a hypothesisEnhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.
P2860
Q24814238-9DCE0362-A4F4-4C12-A34D-12B5B2FEDA0AQ27489000-A5C1A8FB-3734-4545-83AD-EE99B2BB94EBQ28485218-F70F4B00-BBCE-404F-A8DB-FC15D0E2E399Q28646881-06912307-8B06-4E21-8038-61F3DBD42744Q30431941-7FAE53C4-2157-4B75-B961-769EBBA13228Q30436401-8B694AB9-2CBC-4C77-9D5B-BAFFEA59CD88Q30843874-1A85C22C-A1B2-4604-A235-A805FEA49CE2Q31016954-6C71A4E3-2365-4ED0-9E6D-7A71BDAC281FQ31143293-79652AA3-A5D7-4D08-B03E-839528F74B71Q33272711-FA54B954-96FE-42CA-9FF3-2C881C44760AQ33274285-1F09FFBB-0205-4B1F-AFF1-DDC5C74518D7Q33508799-C0B38BBC-7652-43CC-9364-58ADFDEA867AQ33725718-E77896A2-B42D-441D-854B-8B319A74D89CQ33784777-FA64A06D-71B7-45E0-ABFF-3D03A14BC090Q33802126-418A96AD-DCE3-4F74-8A22-C704D2F8CBCCQ33825418-BAAD6449-D2FC-4950-8ED0-AE8CD7657D53Q33826951-5CD77D63-4A50-486C-9A2A-0A4594185F1BQ33835295-7B8A54A6-42F2-4B14-8585-D85003758ACBQ33870236-FF84F5CD-A510-4FB2-B724-B0242D660D9BQ33951963-310077E3-22AD-48C2-BAC4-2C17FF55A305Q33987533-C1942CA8-CF9E-4CDC-84AA-292329E96EC4Q34030981-30645813-B9ED-4226-A828-385A0ACC1A4AQ34299053-0B7A502F-17C5-4A98-9468-3CB1256208B8Q34332284-807969A9-38B9-447E-8445-7CE1A57257CEQ34341098-B4C18026-9EBC-485F-8929-CE5F4EC7478DQ34361680-0B90CA8D-35B0-4A95-9A6D-92C4B77B75BFQ34611144-1C40B812-7C1C-4B0E-B910-1AB91FC12B85Q34637968-94D9324D-5D3C-43EB-B110-55039503BAC3Q34977075-E7685543-36E0-44A0-9501-CC9F5070B204Q34988326-F9698101-5C07-4243-A836-F1DC4288B798Q35110976-220D58B2-4A15-4E04-8F7C-750535AC7370Q35149865-5644BE9B-CBBF-479C-829C-C650EAA9464DQ35651494-66F755B8-B979-497C-9E63-4571A7909607Q35745442-B72408B3-93F3-4AEC-96CA-55FE0DF73FE9Q35857416-D0EFCA1C-7914-40DC-B471-1DB424B894BBQ36037760-4E23715E-13D3-4A22-915D-39629BAFD098Q36103090-B6FCF690-72DC-4DD3-8030-5396F51337E5Q36487151-553C771C-E49F-4153-B8AE-6C254DD4E54DQ36532471-16B07C33-E1CA-49DA-A66E-77FEFECFD51BQ36747750-CFAEEEDE-6BE0-4CBB-9A4F-C8BA78C0FEFB
P2860
Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Epitope map of human immunodef ...... h oligomeric envelope protein.
@ast
Epitope map of human immunodef ...... h oligomeric envelope protein.
@en
type
label
Epitope map of human immunodef ...... h oligomeric envelope protein.
@ast
Epitope map of human immunodef ...... h oligomeric envelope protein.
@en
prefLabel
Epitope map of human immunodef ...... h oligomeric envelope protein.
@ast
Epitope map of human immunodef ...... h oligomeric envelope protein.
@en
P2093
P2860
P1433
P1476
Epitope map of human immunodef ...... h oligomeric envelope protein.
@en
P2093
P2860
P304
P407
P577
1997-04-01T00:00:00Z